#USA #Tucson #Personalized Medicine #Critical Path Institute #One to Millions

Critical Path Institute Launches 'One to Millions'

On March 28, 2026, the Critical Path Institute (C-Path) announced the initiation of 'One to Millions,' a groundbreaking global public-private partnership aimed at reshaping the landscape of personalized medicine. This ambitious initiative seeks to create scalable solutions for the development of advanced therapies tailored for highly individualized diseases, ensuring that patients receive expedited access to vital treatments.

The Need for Change

Recent advancements in technology—especially within the realms of antisense oligonucleotides, gene editing, gene therapies, and RNA-based treatments—have paved the way for precise therapies targeting specific patient groups or even individuals. However, the current regulatory frameworks and reimbursement systems are ill-equipped to manage these developments, leading to a noticeable gap that delays patient access to innovative therapies. This gap necessitates a robust, adaptable framework capable of supporting the evolution of these cutting-edge treatments.

Framework and Collaboration

The 'One to Millions' initiative will leverage C-Path’s centralized, regulatory-compliant data platform to bolster evidence generation, facilitate regulatory decision-making, and promote scalable developmental pathways. According to Dr. Klaus Romero, CEO of C-Path, this effort represents a momentous occasion for transforming lives through improved access to personalized therapies.

C-Path's approach includes a centralized data platform, a unique pre-competitive environment that encompasses the entire ecosystem, integrated outcomes from preclinical, translational, and clinical research, actionable evidence frameworks to evaluate effectiveness and safety, and the tools necessary for securing regulatory approval.

A Call for Systematic Action

Julia Vitarello, founder of Mila's Miracle Foundation and co-founder of the N=1 Collaborative, stressed the urgent need for coordinated action to address the shortcomings of the current healthcare system. As she noted, while scientific breakthroughs in genetics can help many children suffering from severe rare diseases, the existing healthcare infrastructure is not designed to tackle numerous genetic conditions affecting small populations. She expressed enthusiasm for transitioning from the approval of individual drugs for singular diseases to developing processes suitable for multiple conditions, emphasizing the importance of systematic data collection and sharing for learning and improving drug safety and efficacy.

Integrating Post-Market Evidence

A distinctive feature of the 'One to Millions' initiative is its incorporation of post-market evidence generation into the development paradigm. By involving long-term registries in the framework, insights gleaned for regulatory decisions will simultaneously inform payer assessments regarding durability, safety, and efficacy. This integration reduces redundancy and accelerates the learning curve. Dr. Janet Woodcock, a longtime director at the FDA, highlighted the importance of shared analyses and learning experiences to prevent stagnation in progress against devastating monogenic diseases.

Optimizing Drug Development

Improving the integration of existing preclinical, translational, and clinical data streams will facilitate better dose-finding and toxicology assessments. By maximizing reliable data collection, the initiative aims to diminish unnecessary reliance on animal testing while establishing a consistent paradigm of ongoing learning and validation.

Dr. Timothy Yu from Boston Children’s Hospital applauded the initiative as a significant milestone for interventional genetics. He emphasized the modular approach of the framework, enabling developers to share data from diverse therapies targeting various genetic mutations without needing to navigate separate approval processes for each mutation.

Collaboration for a Brighter Future

At the core of this shared initiative are partnerships among notable organizations, including the n-Lorem Foundation, Mila's Miracle Foundation, and N=1 Collaborative. Each brings its expertise and insights garnered from working with patients afflicted by ultra-rare diseases, reinforcing the collective effort to improve access to groundbreaking ASO medications.

Dr. Sarah Glass, COO of n-Lorem, expressed optimism regarding the momentum in addressing challenges faced by the community of patients with extremely rare diseases and underlined their commitment to improving access to tailored therapies.

Conclusion

The 'One to Millions' initiative is more than just a program; it is a paradigm shift towards a healthcare system that embraces innovation, collaboration, and patient-centricity. As stakeholders continue to unite, the objective is clear: to forge pathways that facilitate the development and safe distribution of personalized treatments to millions of patients worldwide, transforming their lives in the process. For more information on this inspirational initiative, please visit c-path.org.